A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)
Todd M. Cooper(Seattle Children's Hospital), Patrick A. Brown(Haemonetics (United States)), Lie Li(Qingdao University), Edward Allan R. Sison(Baylor College of Medicine), Lia Gore(Children's Hospital Colorado), Tanya Trippett(Memorial Sloan Kettering Cancer Center), Michael J. Absalon(Cincinnati Children's Hospital Medical Center), Keith J. August(Children's Mercy Hospital), Margaret E. Macy(Children's Hospital Colorado), Jessica A. Pollard(Maine Medical Center), Sharyn D. Baker(The Ohio State University), Aru Narendran(University of Calgary), Jessica Boklan(University of Arizona), Amina Ahmed(Memorial Sloan Kettering Cancer Center), Daniel Magoon(Johns Hopkins University)
Cited by 73
Related Papers
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341